Oculis Holding AG (OCS) Interest & Investment Income (2022 - 2026)
Quarterly Interest & Investment Income fell 14.53% to $468660.7 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $549.0 million through Mar 2026, down 14.67% year-over-year, with the annual reading at $2.2 million for FY2025, 10.52% down from the prior year.
Oculis Holding AG's Interest & Investment Income history spans 5 years, with the latest figure at $468660.7 for Q1 2026.
- Interest & Investment Income came in at $468660.7 for Q1 2026, up from $399123.2 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $641.7 million in Q3 2024 to a low of $7268.1 in Q2 2022.
- The 5-year median for Interest & Investment Income is $508500.1 (2025), against an average of $74.7 million.
- The largest YoY upside for Interest & Investment Income was 108905.97% in 2024 against a maximum downside of 42.73% in 2024.
- Oculis Holding AG's Interest & Investment Income stood at $58129.2 in 2022, then soared by 1172.24% to $739544.5 in 2023, then tumbled by 42.73% to $423504.6 in 2024, then fell by 5.76% to $399123.2 in 2025, then increased by 17.42% to $468660.7 in 2026.
- Per Business Quant, the three most recent readings for OCS's Interest & Investment Income are $468660.7 (Q1 2026), $399123.2 (Q4 2025), and $547.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 305,000.00 |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | 468,660.72 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 468,660.72 |
| Dec 31, 2025 | 399,123.16 |
| Sep 30, 2025 | 547.55 Mn |
| Jun 30, 2025 | 628,102.92 |
| Mar 31, 2025 | 548,339.51 |
| Dec 31, 2024 | 423,504.61 |
| Sep 30, 2024 | 641.74 Mn |
| Jun 30, 2024 | 729,823.70 |
| Mar 31, 2024 | 665,641.42 |
| Dec 31, 2023 | 739,544.53 |
| Sep 30, 2023 | 588,719.33 |
| Jun 30, 2023 | 240,229.92 |
| Mar 31, 2023 | 35,678.37 |
| Dec 31, 2022 | 58,129.23 |
| Sep 30, 2022 | 63,162.85 |
| Jun 30, 2022 | 7,268.05 |